Going public: Sirtris aims to draw interest in aging drug

Cambridge, Mass.-based Sirtris Pharmaceuticals Inc. seeks to become the first public company developing a new class of drugs to treat age-related diseases by capitalizing on the supposed benefits of a compound found in red wine.

Andrew S. Forman, a WR Hambrecht & Co. biopharmaceutical analyst, said publicity surrounding the health benefits of red wine makes this an opportune time for Sirtris to offer shares to the public _ and gives the company an advantage over similarly situated biopharmaceutical companies.

The science behind the company, which filed this month with the Securities and Exchange Commission to raise up to $60 million in an initial public offering, is based on the well-established observation that many animal species live longer and healthier if their calorie intake is restricted by 30 percent to 40 percent.

Recent scientific studies indicate that the effect of calorie restriction is mimicked by a substance in red wine called resveratrol. Resveratrol activates a group of enzymes called sirtuins that seem to give the benefit of calorie restriction.

More info:  Associated Press article

Advertisements

One Response to “Going public: Sirtris aims to draw interest in aging drug”

  1. Robert Wilton Dale Says:

    I am interested in finding out how to get more information on SRT501. Is there a way to get in a group study of this new research?
    Please send information to: Robert Wilton Dale
    P.O. Box 402
    Tacna, Arizona, 85352
    Or rwd46jr@yahoo.com
    Thank you – Robert Wilton Dale
    Age – 60

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: